We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
+41.99%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$7.04B
AUM Growth
+$1.98B
Cap. Flow
-$1.2B
Cap. Flow %
-17.09%
Top 10 Hldgs %
79.89%
Holding
87
New
12
Increased
14
Reduced
15
Closed
5

Top Buys

Rank Stock Value
1
GEVA
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
+$51.7M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$19.5M
3
DSCI
Derma Sciences, Inc. Common Stock (DE)
DSCI
+$16.6M
4
QCOR
QUESTCOR PHARMA INC
QCOR
+$13.7M
5
XOMA
Xoma
XOMA
+$12.5M

Top Sells

Rank Stock Value
1
PCYC
PHARMACYCLICS INC
PCYC
+$195M
2
VPHM
VIROPHARMA INC
VPHM
+$96M
3
CLVS
Clovis Oncology, Inc.
CLVS
+$15.8M
4
AEGR
Aegerion Pharmaceuticals
AEGR
+$8.82M
5
INFI
Infinity Pharmaceuticals, Inc.
INFI
+$8.22M

Sector Composition

Rank Sector Weight
1 Healthcare 48.27%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PCYC
1
DELISTED
PHARMACYCLICS INC
PCYC
$1.25B 17.71%
9,010,211
-1,760,927
-16% -$195M
SGEN
2
DELISTED
Seagen Inc. Common Stock
SGEN
$847M 12.04%
19,322,947
– –
GEVA
3
DELISTED
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
$651M 9.26%
10,273,182
+1,050,000
+11% +$51.7M
INCY icon
4
Incyte
INCY
$25.9B
$565M 8.03%
14,810,559
– –
ACAD icon
5
Acadia Pharmaceuticals
ACAD
$5.08B
$548M 7.79%
19,955,126
– –
GHDX
6
DELISTED
Genomic Health, Inc.
GHDX
$417M 5.93%
13,650,835
– –
VPHM
7
DELISTED
VIROPHARMA INC
VPHM
$220M 3.12%
5,592,239
-2,936,364
-34% -$96M
XOMA
8
DELISTED
Xoma
XOMA
$103M 1.47%
1,151,619
+137,890
+14% +$12.5M
GILD icon
9
Gilead Sciences
GILD
$181B
$78.3M 1.11%
1,245,800
– –
HALO icon
10
Halozyme
HALO
$12.3B
$77.5M 1.1%
7,017,608
+464,458
+7% +$3.87M
RPRX
11
DELISTED
Repros Therapeutics Inc.
RPRX
$74.5M 1.06%
2,778,654
– –
AEGR
12
DELISTED
Aegerion Pharmaceuticals
AEGR
$70.3M 1%
820,275
-104,068
-11% -$8.82M
CERS icon
13
Cerus
CERS
$566M
$56.8M 0.81%
8,455,306
– –
BMRN icon
14
BioMarin Pharmaceuticals
BMRN
$12.9B
$56.5M 0.8%
783,311
– –
VNDA icon
15
Vanda Pharmaceuticals
VNDA
$319M
$52.5M 0.75%
4,791,179
+825,000
+21% +$8.81M
BCRX icon
16
BioCryst Pharmaceuticals
BCRX
$2.44B
$48.8M 0.69%
6,699,979
+1,136,364
+20% +$5.76M
STML
17
DELISTED
Stemline Therapeutics, Inc.
STML
$36.3M 0.52%
800,400
-99,600
-11% -$3.25M
DSCI
18
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$31.7M 0.45%
2,558,857
+1,200,000
+88% +$16.6M
QCOR
19
DELISTED
QUESTCOR PHARMA INC
QCOR
$31.7M 0.45%
545,846
+230,000
+73% +$13.7M
MRTX
20
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$30M 0.43%
+1,980,074
New +$19.5M
ICPT
21
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$25M 0.36%
362,847
-100,000
-22% -$4.94M
ARIA
22
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$24.5M 0.35%
1,333,703
-116,297
-8% -$2.26M
MDVN
23
DELISTED
MEDIVATION, INC.
MDVN
$23.9M 0.34%
796,662
– –
PGNX
24
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$21.1M 0.3%
4,200,000
– –
AVNR
25
DELISTED
AVANIR PHARMACEUTICALS, INC CL A
AVNR
$18.7M 0.27%
4,428,591
+850,000
+24% +$4.03M
1
2 3 4

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q3 2013 Portfolio in Review

As of Q3 2013, Julian Baker held 87 positions worth $7.04B, up 39% from $5.06B the previous quarter. Its ten largest holdings account for 80% of the portfolio.

Julian Baker withdrew a net $1.2B in Q3 2013, closing 5 positions and reducing 15 holdings. Its most notable exit was Arqule Inc, an estimated $2.04M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 48% of assets, up from 48% a quarter earlier.

Against the trend, Julian Baker opened a new position in Mirati Therapeutics, Inc. Common Stock worth $30M.

  • Julian Baker's largest Q3 2013 buy was Mirati Therapeutics, Inc. Common Stock: 1,980,074 shares worth $30M.
  • Julian Baker added most to SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q3 2013, an estimated $51.7M increase.
  • Julian Baker's biggest Q3 2013 reduction was PHARMACYCLICS INC, cutting an estimated $195M.
  • Julian Baker fully exited Arqule Inc in Q3 2013, selling an estimated $2.04M.
  • Julian Baker's ten largest holdings make up 80% of its $7.04B portfolio in Q3 2013.
  • Julian Baker opened 12 new positions and closed 5 in Q3 2013.
  • Julian Baker's portfolio value rose 39% quarter-over-quarter to $7.04B.

Based on Baker Bros. Advisors's 13F filing for Q3 2013, filed 14 Nov 2013.